OrthoPediatrics Corp. (NASDAQ:KIDS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $34.1429.

Several analysts have recently weighed in on KIDS shares. Citigroup restated a “market outperform” rating on shares of OrthoPediatrics in a research report on Friday, August 8th. BTIG Research reduced their price target on shares of OrthoPediatrics from $40.00 to $39.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Wall Street Zen upgraded shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, JMP Securities set a $35.00 target price on OrthoPediatrics and gave the stock a “market outperform” rating in a research report on Friday, August 8th.

OrthoPediatrics Trading Down 2.0%

NASDAQ:KIDS opened at $20.49 on Wednesday. OrthoPediatrics has a 1 year low of $16.59 and a 1 year high of $33.14. The stock has a market cap of $513.68 million, a P/E ratio of -11.45 and a beta of 1.06. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.43 and a current ratio of 6.66. The stock has a 50-day simple moving average of $21.05 and a 200-day simple moving average of $21.94.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, August 5th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. The firm had revenue of $61.08 million during the quarter, compared to analysts’ expectations of $61.40 million. OrthoPediatrics had a negative return on equity of 6.36% and a negative net margin of 18.92%. OrthoPediatrics has set its FY 2025 guidance at EPS. As a group, analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Insider Transactions at OrthoPediatrics

In other news, CFO Fred Hite purchased 5,076 shares of the business’s stock in a transaction on Thursday, August 21st. The shares were bought at an average price of $19.41 per share, with a total value of $98,525.16. Following the completion of the transaction, the chief financial officer directly owned 213,065 shares in the company, valued at approximately $4,135,591.65. This represents a 2.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On OrthoPediatrics

A number of hedge funds have recently modified their holdings of the business. Los Angeles Capital Management LLC purchased a new stake in OrthoPediatrics in the 2nd quarter valued at $220,000. PDT Partners LLC purchased a new stake in shares of OrthoPediatrics in the first quarter valued at about $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after buying an additional 645 shares during the period. GAMMA Investing LLC grew its holdings in shares of OrthoPediatrics by 4,618.2% during the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company’s stock worth $261,000 after buying an additional 10,391 shares during the last quarter. Finally, R Squared Ltd purchased a new position in shares of OrthoPediatrics during the second quarter worth about $272,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.